Abstract:Background Acute heart failure is the most frequent cause of unplanned hospital admission in elderly patients. Various biomarkers have been evaluated to better assess the status of these patients and prevent decompensation. Recently, voice has been suggested as a cost‐effective and noninvasive way to monitor disease progression. This study evaluates speech and pause alterations in patients with acute decompensated and stable heart failure. Specifically, we aim to identify a vocal biomarker that could be used to monitor patients with heart failure and to prevent decompensation. Methods and Results Speech and pause patterns were evaluated in 68 patients with acute and 36 patients with stable heart failure. Voice recordings were performed using a web‐browser based application that consisted of 5 tasks. Speech and pause patterns were automatically extracted and compared between acute and stable patients and with clinical markers. Compared with stable patients, pause ratio was up to 14.9% increased in patients with acute heart failure. This increase was largely independent of sex, age, and ejection fraction and persisted in patients with lower degrees of edema or dyspnea. Furthermore, pause ratio was positively correlated with NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) after controlling for acute versus stable heart failure. Collectively, our findings indicate that the pause ratio could be useful in identifying acute heart failure, particularly in patients who do not display traditional indicators of decompensation. Conclusions Speech and pause patterns are altered in patients with acute heart failure. Particularly, we identified pause ratio as an easily interpretable vocal biomarker to support the monitoring of heart failure decompensation. Nonstandard Abbreviations and Acronyms AHF acute heart failure MAD mean articulation duration MPD mean pause duration NYHA New York Heart Association OP outpatient clinic PR pause ratio RST rate of speech timing (speech rate) Clinical Perspective What Is New? This study adopted the Stroop test as a reading test and used automated voice segmentation to quantify speech and pause time in patients with stable and patients with acute heart failure. Comparing speech and pause times between patients with stable and patients with acute heart failure identified novel alterations in acute patients. What Are the Clinical Implications? The results highlight the potential of voice tests as a complementary measure that supports health care professionals and patients in the monitoring of heart failure and early identification of heart failure decompensation. Heart failure (HF) is a chronic condition caused by structural or functional cardiac abnormalities, resulting in symptoms such as breathlessness, fatigue, and edema. HF affects around 26 million people worldwide, and the numbers are expected to increase exponentially. 1 Patients with HF can be stable, but progression of the underlying conditions or other changes in health can result in acute decompensated HF, which accounts for the majority of HF hospitalizations. 2 , 3 Each HF‐related hospitalization increases the risk for subsequent hospitalization events 4 and despite current treatments, rates of hospital admissions for HF are still high. Therefore, improvements in outpatient management are needed to address the increasing burden of HF. Recently, voice assessment has been suggested as a cost‐effective and noninvasive tool for coronary artery disease. 5 Changes in voice patterns have been identified in patients with decompensated HF 6 or pulmonary congestion. 7 Additionally, changes in vocal characteristics were associated with adverse outcomes among patients with HF. 8 These findings suggest a potential of voice as a novel biomarker to monitor patients with HF noninvasively. However, its application in clinical practice -Abstract Truncated-

Cluster analysis of volatile organic compounds - a pilot study in patients with severe acute decompensated heart failure

Novel Biomarkers as Potential Predictors of Decompensated Advanced Chronic Heart Failure—Single Center Study

Analysis of Volatile Organic Compounds in Exhaled Air in Patients with Sickle Cell Disease during Vaso-Occlusive Episodes

Analysis of volatile organic compounds in the breath of patients with stable or acute exacerbation of chronic obstructive pulmonary disease

Evaluation of urinary volatile organic compounds as a novel metabolomic biomarker to assess chronic kidney disease progression

Analysis of Volatile Compounds in Exhaled Breath Condensate in Patients with Severe Pulmonary Arterial Hypertension

Metabolic Profiling Identifies 1-MetHis and 3-IPA as Potential Diagnostic Biomarkers for Patients With Acute and Chronic Heart Failure With Reduced Ejection Fraction

Breath octane and acetaldehyde as markers for acute respiratory distress syndrome in invasively ventilated patients suspected to have ventilator-associated pneumonia

Breath Analysis via Gas Chromatography-Mass Spectrometry (GC-MS) in Chronic Coronary Syndrome (CCS): A Proof-of-Concept Study

Breath Analysis: Identification of Potential Volatile Biomarkers for Non-Invasive Diagnosis of Chronic Kidney Disease (CKD)

Utility of Initial Prehospital End-tidal Carbon Dioxide Measurements to Predict Poor Outcomes in Adult Asthmatic Patients

Volatile organic compounds from exhaled breath in schizophrenia

Exhaled volatile organic compounds as markers for medication use in asthma

Biologically active adrenomedullin as a marker for residual congestion and early rehospitalization in patients hospitalized for acute heart failure: Data from STRONG‐HF

Machine Learning Model Based on Transthoracic Bioimpedance and Heart Rate Variability for Lung Fluid Accumulation Detection: Prospective Clinical Study

Thoracic Fluid Content as an Indicator of High Intravenous Diuretic Requirements in Hospitalized Patients with Decompensated Heart Failure

Evaluation Of The Degree Of Decongestion Among Patients Admitted With Acutely Decompensated Heart Failure Utilizing The Novel HEMOTAGTM Cardiopulmonary Assessment System

Unbiased clustering and molecular characterisation of novel metabolic phenotypes in a heart failure cohort

Are Ambient Volatile Organic Compounds Environmental Stressors for Heart Failure?

Evaluation of Speech and Pause Alterations in Patients With Acute and Chronic Heart Failure

Breath analysis combined with cardiopulmonary exercise testing and echocardiography for monitoring heart failure patients: the AEOLUS protocol